van Asch, C J, Luitse, M J, Rinkel, G J, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurology. 2010; 9:167–76.Google Scholar

Flaherty, M L, Kissela, B, Woo, D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21.Google Scholar

Huhtakangas, J, Tetri, S, Juvela, S, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: A longitudinal population-based study. Stroke. 2011; 42:2431–5.Google Scholar

Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.Google Scholar

Jeffree, R L, Gordon, D H, Sivasubramaniam, R, Chapman, A. Warfarin related intracranial haemorrhage: A case-controlled study of anticoagulation monitoring prior to spontaneous subdural or intracerebral haemorrhage. Journal of Clinical Neuroscience. 2009; 16:882–5.Google Scholar

Dequatre-Ponchelle, N, Henon, H, Pasquini, M, et al. Vitamin K antagonists-associated cerebral hemorrhages: What are their characteristics? Stroke. 2013; 44:350–5.Google Scholar

Keeling, D, Baglin, T, Tait, C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology. 2011; 154:311–24.Google Scholar

Limdi, N A, Veenstra, D L. Warfarin pharmacogenetics. Pharmacotherapy. 2008; 28:1084–97.Google Scholar

Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care. 2012; 16:203–9.Google Scholar

Di Nisio, M, Middeldorp, S, Buller, H R. Direct thrombin inhibitors. New England Journal of Medicine. 2005; 353:1028–40.Google Scholar

van Ryn, J, Stangier, J, Haertter, S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis. 2010; 103:1116–27.Google Scholar

Yeh, C H, Fredenburgh, J C, Weitz, J I. Oral direct factor Xa inhibitors. Circulation Research. 2012; 111:1069–78.Google Scholar

Kamal, A H, Tefferi, A, Pruthi, R K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clinic Proceedings. 2007; 82:864–73.Google Scholar

Miyares, M A, Davis, K. Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient. American Journal of Health-System Pharmacy. 2012; 69:1473–84.Google Scholar

Samama, M M, Martinoli, J L, LeFlem, L, et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis. 2010; 103:815–25.Google Scholar

Samama, M M, Guinet, C. Laboratory assessment of new anticoagulants. Clinical Chemistry and Laboratory Medicine. 2011; 49:761–72.Google Scholar

Stangier, J, Rathgen, K, Stahle, H, Gansser, D, Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology. 2007; 64:292–303.Google Scholar

Lippi, G, Favaloro, E J. Activated partial thromboplastin time: New tricks for an old dogma. Seminars in Thrombosis and Hemostasis. 2008; 34:604–11.Google Scholar

Wong, P C, Crain, E J, Xin, B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis. 2008; 6:820–9.Google Scholar

Bara, L, Mardiguian, J, Samama, M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thrombosis Research. 1990; 57:585–92.Google Scholar

Harder, S, Parisius, J, Picard-Willems, B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): Relation to FXa-activity and influence of assay modifications. Thrombosis Research. 2008; 123:396–403.Google Scholar

Qureshi, A I, Tuhrim, S, Broderick, J P, et al. Spontaneous intracerebral hemorrhage. New England Journal of Medicine. 2001; 344:1450–60.Google Scholar

Goldstein, J N, Gilson, A J. Critical care management of acute intracerebral hemorrhage. Current Treatment Options in Neurology. 2011; 13:204–16.Google Scholar

Masotti, L, Di Napoli, M, Godoy, D A, et al. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. International Journal of Stroke. 2011; 6:228–40.Google Scholar

Qureshi, A I. Intracerebral hemorrhage specific intensity of care quality metrics. Neurocritical Care. 2011; 14:291–317.Google Scholar

Goodnough, L T, Shander, A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011; 117:6091–9.Google Scholar

Riegert-Johnson, D L, Volcheck, G W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): A 5-year retrospective review. Annals of Allergy, Asthma & Immunology. 2002; 89:400–6.Google Scholar

Aguilar, M I, Hart, R G, Kase, C S, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clinic Proceedings. 2007; 82:82–92.Google Scholar

Benjamin, R J, McLaughlin, L S. Plasma components: Properties, differences, and uses. Transfusion. 2012; 52(Suppl 1):9S–19S.Google Scholar

Goldstein, J N, Thomas, S H, Frontiero, V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006; 37:151–5.Google Scholar

Goodnough, L T. A reappraisal of plasma, prothrombin complex concentrates, and recombinant factor VIIa in patient blood management. Critical Care Clinics. 2012; 28:413–26.Google Scholar

Silliman, C C, McLaughlin, N J. Transfusion-related acute lung injury. Blood Reviews. 2006; 20:139–59.Google Scholar

Pandey, S, Vyas, G N. Adverse effects of plasma transfusion. Transfusion. 2012; 52(Suppl 1):65S–79S.Google Scholar

Fredriksson, K, Norrving, B, Stromblad, L G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992; 23:972–7.Google Scholar

Huttner, H B, Schellinger, P D, Hartmann, M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006; 37:1465–70.Google Scholar

Switzer, J A, Rocker, J, Mohorn, P, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012; 43:2500–2.Google Scholar

Wiedermann, C J, Stockner, I. Warfarin-induced bleeding complications: clinical presentation and therapeutic options. Thrombosis Research. 2008; 122(Suppl 2):S13–18.Google Scholar

Dager, W E, King, J H, Regalia, R C, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006; 26:1091–8.Google Scholar

Mayer, S A, Brun, N C, Begtrup, K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine. 2005; 352:777–85.Google Scholar

Mayer, S A, Brun, N C, Begtrup, K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine. 2008; 358:2127–37.Google Scholar

Narayan, R K, Maas, A I, Marshall, L F, et al. Recombinant factor VIIa in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial. Neurosurgery. 2008; 62:776–86.CrossRefGoogle ScholarPubMed

Yuan, Z H, Jiang, J K, Huang, W D, et al. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. Journal of Clinical Neuroscience. 2010; 17:685–93.Google Scholar

Morgenstern, L B, Hemphill, J C 3rd, Anderson, C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41:2108–29.Google Scholar

Pernod, G, Godier, A, Gozalo, C, et al. French National Authority for H. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thrombosis Research. 2010; 126:e167–74.Google Scholar

Shander, A G L, Ratko, T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (novoseven) therapy. Pharmacol Ther. 2005; 644.Google Scholar

Vincent, J L, Rossaint, R, Riou, B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: A European perspective. Critical Care. 2006; 10:R120.Google Scholar

Rosovsky, R P, Crowther, M A. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology. 2008;36–8.Google Scholar

Fernandes, H M, Siddique, S, Banister, K, et al. Continuous monitoring of ICP and CPP following ICH and its relationship to clinical, radiological and surgical parameters. Acta Neurochirurgica. Supplement. 2000; 76:463–6.Google Scholar

Brott, T, Adams, H P Jr., Olinger, C P, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989; 20:864–70.Google Scholar

Teasdale, G, Jennett, B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974; 2:81–4.Google Scholar

Diringer, M N, Edwards, D F. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Critical Care Medicine. 2001; 29:635–40.Google Scholar

Flaherty, M L, Tao, H, Haverbusch, M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71:1084–9.Google Scholar

Steiner, T, Rosand, J, Diringer, M. Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions. Stroke. 2006; 37:256–62.Google Scholar

Webb, H D, Griffin, C A. Cytogenetic study of acoustic neuroma. Cancer Genetics and Cytogenetics. 1991; 56:83–4.Google Scholar

Schulman, S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. New England Journal of Medicine. 2003; 349:675–83.Google Scholar

Qureshi, A I, Majidi, S, Chaudhry, S A, Qureshi, M H, Suri, M F. Validation of intracerebral hemorrhage-specific intensity of care quality metrics. Journal of Stroke and Cerebrovascular Diseases. 2013; 22:661–7.Google Scholar

Fernlof, G, Sjostrom, B M, Lindell, K M, Wall, U E. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood coagulation & Fibrinolysis. 2009; 20:667–74.Google Scholar

Monroe, D M, Hoffman, M, Oliver, J A, Roberts, H R. Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology. 1997; 99:542–7.Google Scholar

Leissinger, C A, Blatt, P M, Hoots, W K, Ewenstein, B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. American Journal of Hematology. 2008; 83:137–43.Google Scholar

Stangier, J, Rathgen, K, Stahle, H, Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clinical Pharmacokinetics. 2010; 49:259–68.Google Scholar

Crawley, F, Bevan, D, Wren, D. Management of intracranial bleeding associated with anticoagulation: Balancing the risk of further bleeding against thromboembolism from prosthetic heart valves. Journal of Neurology, Neurosurgery, and Psychiatry. 2000; 69:396–8.Google Scholar

Punthakee, X, Doobay, J, Anand, S S. Oral-anticoagulant-related intracerebral hemorrhage. Thrombosis Research. 2002; 108:31–6.Google Scholar

Phan, T G, Koh, M, Wijdicks, E F. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Archives of Neurology. 2000; 57:1710–13.Google Scholar

Wijdicks, E F, Schievink, W I, Brown, R D, Mullany, C J. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998; 42:769–73.Google Scholar

Leker, R R, Abramsky, O. Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology. 1998; 50:1489–91.Google Scholar

Bertram, M, Bonsanto, M, Hacke, W, Schwab, S. Managing the therapeutic dilemma: Patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. Journal of Neurology. 2000; 247:209–14.Google Scholar

Butler, A C, Tait, R C. Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: A 2-year follow-up. British Journal of Haematology. 1998; 103:1064–6.Google Scholar

Kawamata, T, Takeshita, M, Kubo, O, et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surgical Neurology. 1995; 44:438–42.Google Scholar

Babikian, V L, Kase, C S, Pessin, M S, Caplan, L R, Gorelick, P B. Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke. 1988; 19:407–8.Google Scholar

Gomez, C R, Sandhu, J, Mehta, P. Resumption of anticoagulation during hypertensive cerebral hemorrhage with prosthetic heart valve. Stroke. 1988; 19:407.Google Scholar